SCHEMBL206190

SCHEMBL206190

Fc1cc(Nc2nc(-c3ccc(-c4csnn4)cc3)cs2)ccc1OCC1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 6/20 0.42
PTGES O14684 1/20 0.41
MCHR1 Q99705 1/20 0.39
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
PTGS2 P35354 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
NPY5R Q15761 1/20 0.38
POLB P06746 1/20 0.38
CYP1B1 Q16678 2/20 0.37
CYP1A1 P04798 1/20 0.37
CYP1A2 P05177 1/20 0.37
GAA P10253 2/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
AMY1A P0DUB6 1/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL208981 0.90 ALOX5 (0.49) ALOX5PTGESMAPTSMN1; SMN2TDP1
SCHEMBL206268 0.85 PTGES (0.42) ALOX5PTGESMCHR1MAPTSMN1; SMN2
SCHEMBL207413 0.85 SPHK1 (0.46) ALOX5
SCHEMBL205720 0.85 PTGES (0.44) ALOX5PTGESMCHR1MAPTSMN1; SMN2
SCHEMBL209003 0.84 PTGES (0.41) ALOX5PTGESMCHR1MAPTSMN1; SMN2
SCHEMBL205926 0.84 PTGES (0.42) ALOX5PTGESMCHR1PTGS2NPC1
SCHEMBL208207 0.82 PTGES (0.45) ALOX5PTGESMCHR1MAPTSMN1; SMN2
SCHEMBL205935 0.82 MEN1 (0.55) MAPTSMN1; SMN2TDP1NPC1RAB9A
SCHEMBL205965 0.82 PSEN1 (0.48) ALOX5PTGESMCHR1MAPTSMN1; SMN2
SCHEMBL2694808 0.81 MAOA (0.49) ALOX5PTGESMAPTSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 ALOX5 3410/4885PTGES 2882/4885MCHR1 3385/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 ALOX5 3410/4885PTGES 2882/4885MCHR1 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.